A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

Condition studied

Propionic Acidemia

Investigational medicinal product(s)

Eligibility

Primary endpoint

Incidence and severity of AEs (including mRNA-3927 -related and not related AEs), SAEs, and AEs leading to treatment discontinuation.

Endpoint detail

Annualized frequency of Investigator-reported MDEs., Annualized frequency of Investigator-reported MDE-related hospitalizations., Annualized frequency of Investigator-reported PA-related hospitalizations., Annualized frequency of Investigator-reported PA-related urgent healthcare encounters.